Since the entry into force of the 2023 update to Annex 1 of the EU GMP Guidelines (Eudralex Volume 4), which introduces new requirements for the manufacture of sterile medicinal products, the implementation of a contamination control strategy (CCS) has also been required in the field of cell and gene therapy.
Do you have any questions about CCS, the production of ATMPs or are you looking for support regarding an ongoing cell and gene therapy project?
Are you planning the construction, qualification and validation of a production facility for cell and gene therapy products or for classic pharmaceuticals?
Visit the joint booth A43 of Valicare & Telstar to meet experts for your request. Both companies are part of the Syntegon Group and have decades of experience in planning, building and qualifying production facilities around the world. Whether you are looking to build a new site or improve an existing one - wherever you are - we offer integrated knowledge, technology and a full range of EPCMV services.
In addition to the construction of a GMP-compliant production facility, we qualify your rooms and facilities, support the transfer, implementation and complete validation of the process with a special focus on cell and gene therapies.
We accompany your project from vision to operation.
📍 Location: Hotel Catalonia Barcelona Plaza, Barcelona
🗓️ Date: April 21-22, 2026
ℹ️ Program: 2. Advanced Therapies Forum
➡️ Registration: Medicalforum & Hospitalforum
